Category: Life Sciences

Page: 2 of 2Page 2 de 212

Prescription for Law: The World of Pharmaceuticals and Medical Devices

October 28, 2015

Blakes hosted a special full-day program focused on the life sciences industry. The program will included updates on legal developments and trends as well as strategies to identify and minimize common risks. Topics included privacy, cybersecurity, personalized medicine, litigation risk management, Bill C-17and transparency measures, competition issues in IP, procurement, anti-corruption and integrity, patient group relationships and social media, all…

Canadian Government to Ban Microbeads in Personal Care Products

August 24, 2015

  The Canadian government has published a proposed Order to add plastic microbeads to the Toxic Substances List and has announced it is developing regulations to ban their use.     Microbeads are synthetic polymer particles manufactured to be larger than 0.1 micrometer and smaller than or equal to five millimeters and are commonly used in personal care products such as…

B.C. Court Finds Methodology to Prove Causation is Required to Certify Pharmaceutical Class Actions

February 4, 2015

  INTRODUCTION   On January 22, 2015, the British Columbia Court of Appeal set aside certification of a class action against Apotex Inc. and Abbott Laboratories Ltd. in Charlton v. Abbott Laboratories Ltd. (Charlton), in which the plaintiffs allege that the medicine sibutramine (sold under the brand name Meridia by Abbott), an antidepressant that is also used for weight loss,…

Recall, Report, Relabel: Bill C-17 Increases Oversight of Drugs and Medical Devices

November 10, 2014

  Bill C-17, An Act to Amend the Food and Drugs Act (Bill), received royal assent on November 6, 2014. The Bill applies to medical devices and prescription and over-the-counter drugs (collectively, therapeutic products), but does not apply to natural health products.   The Bill grants the Minister of Health (Minister) substantial new powers, including the power to order recalls,…

Pot of Gold: The Commercialization of Medical Marijuana

April 3, 2014

  On April 1, 2014, the new Marihuana for Medical Purposes Regulations (MMPR) supplanted the 13-year-oldMarihuana Medical Access Regulations (MMAR). The MMPR overhauls Health Canada’s medical marijuana program by replacing a system of small-scale home growers with a commercial network of licensed producers. Although a recent Federal Court decision has temporarily exempted certain home growers from the repeal of the MMAR, licensed producers…

Page: 2 of 2Page 2 de 212